Sex: M
Vaccine: COVID19, UNK
Symptoms: Prescribed underdose, Thrombosis, Weight
Clinical narrative: BLOOD CLOT; STARTED BACK UP ON ELIQUIS AT 7.5 MG BID; This is a spontaneous report received from a contactable reporter(s) (Physician) from License Party. Other Case identifier(s): US-BRISTOL-MYERS SQUIBB COMPANY-2022-134774 (Bristol-Myers Squibb Company).  Information was received from a Physician concerning a 68 Year(s) old Male patient, who received Suspect product APIXABAN for Product used for unknown indication (5 milligram(s) 2 every 1 Day); Suspect product COVID-19 VACCINE for Product used for unknown indication, lot number:Unknown. On an unknown date, the patient experienced thrombosis(blood clot) which was considered serious due to medical significance. It is unknown if treatment was provided. The outcome of the event is unknown. On an unknown date, the patient experienced prescribed underdose(started back up on eliquis at 7.5 mg bid) which was considered not serious. It is unknown if treatment was provided. The outcome of the event is unknown. APIXABAN was discontinued. The status of COVID-19 VACCINE medication is unknown. Concomitant medications were not reported. The reporter did not provide a causal assessment for events thrombosis and prescribed underdose to product APIXABAN. The reporter considered event thrombosis related to product COVID-19 VACCINE. The reporter considered event prescribed underdose not related to product COVID-19 VACCINE. Patient had a breakthrough blood clot while taking 5 mg BID of eliquis. He was around 350 pounds. She has also been working with a hematologist after the incident. They tried switching him to Lovenox after clot however he started coughing up blood. They have since started back up on Eliquis at 7.5 mg BID. She was hoping for some guidance on dosage and any information on Eliquis usage in obese patients. She was thinking Covid vaccines/boosters have instigated clotting, his last booster was a few months ago. She also stated her pharmacy team has seen more breakthrough clots in obese patients. The strength of apixaban was 5 mg. Tracking of Changes: 08-Nov-2022: Initial information was received.  Eliquis is under agreement with BRISTOL-MYERS SQUIBB.; Sender's Comments: This patient had blood clot while on therapy with apixaban. Based on the available information, it cannot be ascertained with reasonable possibility that the suspect drug contributed to the reported events and hence is unrelated to suspect therapy.  Pfizer comment: Based on the information provided, there is no information to suggest a causal relationship between COVID-19 Vaccine - (Manufacturer Unknown) and the reported event of thrombosis. Vaccination date and event onset dates were not provide at this time. Case will be reassessed upon receipt of additional information. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics committees and Investigators, as appropriate.